CD8A and neoplasm: To evaluate the effect of the combination on the endogenous T-cell response, the percentage of host CD8 T cells specific for two immunodominant CD8 T-cell epitopes of B16OVA tumors, such as the M8 and OVA epitopes, was assessed using H2-Kb-tetramers in treated and non-treated tumors, LNs (both DLN and CLN (relative to the STING-L-treated tumor)) and peripheral blood.